Genvor Inc
genvor.comWhat Do They Do?
Develops AI-designed peptide technologies for crop protection and plant health, including seed traits and biological sprays for agricultural growers.
10-K for FY2025, filed Dec 10, 2025The Company, through its wholly owned subsidiary Genvor Inc., is pioneering the development and commercialization of AI-accelerated peptide…View ↗
The Company’s technology platform encompasses multiple classes of engineered peptides designed to address distinct agricultural challenges.…View ↗
The Company’s platform centers on the development of anti-microbial peptides (“AMPs”), which are designed to combat a broad spectrum of…View ↗
Commercialization of Genvor’s peptide technologies is a key strategic priority, with an initial focus on developing seed trait integrations…View ↗
How Do They Make Money?
No revenue reported yet.
10-K for FY2021, filed Mar 21, 2022
Who Are Their Customers?
Agricultural organizations are its intended commercialization partners through licensing, joint-development and research arrangements; its crop solutions target conventional and organic growers.
10-K for FY2025, filed Dec 10, 2025Genvor's approach to market entry emphasizes capital efficiency through strategic partnerships rather than internal infrastructure…View ↗
The Company employs a licensing-first commercialization model, forming strategic partnerships and joint development agreements (JDAs) that…View ↗
All of Genvor’s peptides are composed of naturally derived amino acid sequences and are developed without the use of toxic chemicals. As a…View ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q3 FY2026, filed Aug 14, 2026
−$2.6MView ↗
- ▲ +543% (Loss)
- vs −$397.8K in Q3 FY2025
-
May 21, 2026
Genvor appointed Donald Kalkofen as chief financial officer
Sources
8-K, filed May 21, 2026
On May 18, 2026, the board of directors (the “Board”) of Genvor Incorporated (the “Company”) appointed Donald Kalkofen as the Company’s…View ↗
Animal-health applications
The older report centers on disease-resistant and nutritionally enhanced corn seed; the latest extends peptide research to animal feed and livestock and aquaculture health.
10-K for FY2022, filed Mar 28, 2023 10-K for FY2025, filed Dec 10, 2025Dr. Jaynes, one of Genvor’s founders, has been on a 30+ year quest to find a global crop solution for defense against Aflatoxins. As a…View ↗
The Company’s strategic vision extends beyond crop protection to encompass the broader agricultural value chain. Genvor is actively…View ↗
In addition to its agricultural applications, Genvor is expanding its research into nutritionally enhanced peptides (“NEPs”) for use in…View ↗
Concurrently, Genvor is pursuing research and validation of its nutritionally enhanced peptides (NEPs), which are designed to significantly…View ↗
Loading...
